Mpm Oncology Innovations Fund Lp
10% Owner at Aktis Oncology, Inc. (AKTS); 10% Owner at Werewolf Therapeutics, Inc. (HOWL)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
—
Avg. 90-day return-14.3%
vs. S&P 500-15.1%
Beat the market0%
Paper profit on buys+$167K
Total bought / sold$20.0M / $392K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jan 14SEC | AKTSAktis Oncology, Inc. | Buy | 1,112,77710,260,064 held (+12%) | $18.00 | $20.0M | +0.8% |
| Nov 3SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 86,9366,355,717 held (−1%) | $1.43 | $124K | -31.5% |
| Nov 3SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 114,0446,241,673 held (−2%) | $1.28 | $146K | -23.4% |
| Nov 3SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 94,0636,147,610 held (−2%) | $1.29 | $121K | -24.0% |
- Buy
10% Owner Mpm Oncology Innovations Fund Lp bought $20.0M of AKTS at $18.00 — first open-market purchase in our records.
- Sell
10% Owner Mpm Oncology Innovations Fund Lp sold $124K of HOWL at $1.43 — pre-scheduled 10b5-1 plan sale.
- Sell
10% Owner Mpm Oncology Innovations Fund Lp sold $146K of HOWL at $1.28 — pre-scheduled 10b5-1 plan sale.
- Sell
10% Owner Mpm Oncology Innovations Fund Lp sold $121K of HOWL at $1.29 — pre-scheduled 10b5-1 plan sale.